Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 9Unknown 6Active not recruiting 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Glioma 2Simpson-Golabi-Behmel syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 9Methotrexate 9Cytarabine 9fludarabine phosphate 8fludarabine 8Radiotherapy 7Vincristine 5Cyclosporine 5Whole-Body Irradiation 4Prednisone 4Mycophenolic Acid 4Melphalan 4Filgrastim 4Etoposide 4Busulfan 4asparaginase erwinia chrysanthemi recombinant 3Tacrolimus 3Sirolimus 3Dasatinib 3Cord Blood Stem Cell Transplantation 3Bortezomib 3Asparaginase 3prednylidene 2pegaspargase 2ixazomib 2deltacortene 2blinatumomab 2Thiotepa 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Immunotherapy, Adoptive × Clear all
NCT03768310 2022-07-21

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

Baylor College of Medicine

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡